September 17, 2015

Aurobindo Pharma’s received approval from the Food and Drug Administration this week for its generic of Roxane Laboratories’ Dolophine (methadone HCL) tablets. 

September 11, 2015

Using Xerox’s prescription clinical authorization tool, pharmacists can investigate whether a patient recently received an opioid prescription and will receive a notice to acquire prior authorization before dispensing it. 

September 3, 2015

Lupin Pharmaceuticals on Thursday announced the launch of its duloxetine delayed-release, a generic version of Cymbalta.

August 11, 2015

Iressa is a once-daily oral medication that targets and blocks the activity of epidermal growth factor receptor-tyrosine kinase.

August 10, 2015

The company’s memantine hydrochloride tablets, available in 5- and 10-mg dosage strengths, are meant to treat dementia associated with Alzheimer’s disease.

July 14, 2015

Both Mylan and Dr. Reddy’s Laboratories have announced the launch of their generic version of dementia drug Namenda.

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 


December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

September 12, 2014

A deficiency of a single vitamin, B1 (thiamine), can cause a potentially fatal brain disorder called Wernicke encephalopathy.

June 27, 2014

Dr. Reddy's Labs on Friday announced the launch of duloxetine delayed-release capsules USP in 20 mg, 30 mg and 60 mg dosage strengths.

June 2, 2014

Greenstone on Tuesday announced the introduction of nadolol tablets to its generic pharmaceutical product line. The drug is available in dosage strengths of 20-mg x 100, 40-mg x 100 and 80-mg x 100.

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

March 17, 2014

Pierre Fabre Dermatologies announced that it received authorization from the Food and Drug Administration to market the pediatric drug Hemangeol (propranolol hydrochloride).

December 11, 2013

The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said.

December 3, 2013

Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

September 25, 2013

Mylan is challenging the patent protection on a drug used to treat fibromyalgia, prompting a lawsuit from the branded drug's manufacturers.

September 16, 2013

A drug for treating opioid dependence has been launched, the manufacturer said Monday.

September 9, 2013

Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand.

August 19, 2013

Specialty pharmacy CareMed Pharmaceutical Services has been added to a limited-distribution network for a cancer drug sold by Genentech and Astellas Pharma, the company said.

July 24, 2013

Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said.

July 2, 2013

A cancer drug made by Genentech and Astellas is no longer available through ordinary retail channels and is now available only through a limited-distribution network.

May 15, 2013

The Food and Drug Administration has approved a drug for a type of lung cancer.

April 24, 2013

The Food and Drug Administration has approved a new drug for constipation related to use of opioid painkillers made by Sucampo Pharmaceuticals and Takeda Pharmaceuticals, the drug makers said.